Conjugate pneumococcal vaccine (13-Valent) for immunocompromised populations: a review of the clinical evidence
CADTH
Record ID 32014000770
English
Authors' recommendations:
The PCV13 vaccine was observed to be non-inferior, and for many serotypes superior, when compared with the PPSV23 vaccine in non-immunocompromised adults who are 65 years of age and older. Additional studies are necessary to ensure that PCV13 confers non-inferior immune responses when compared with PPSV23 in more representative older populations, including those that are immunocompromised and those that are residing in either nursing homes or long-term care facilities. There remains a paucity of evidence for the effectiveness of PCV13 in populations of adults with HIV infection, sickle cell disease, those having undergone either hematopoietic stem cell or solid organ transplant, and in those receiving immunosuppressive treatments.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/may-2014/RC0543%20Prevnar-13%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Immunocompromised Host
- Vaccination
- Pneumococcal Vaccines
- Pneumococcal Infections
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.